Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Une comparaison de la thérapie cognitivo-comportementale de groupe (TCC) et du groupe d'activités structurées pour les adultes souffrant de trouble déficitaire de l'attention avec hyperactivité (TDAH)

16 septembre 2026 mis à jour par: Vastra Gotaland Region

Un essai contrôlé randomisé en simple aveugle sur la thérapie cognitivo-comportementale de groupe (TCC) par rapport à la condition de contrôle de groupe d'activité pour les adultes souffrant de trouble déficitaire de l'attention avec hyperactivité (TDAH)

Many adults with attention deficit hyperactivity disorder (ADHD) experience difficulties with inattention, planning and impulsivity that impacts work and social life negatively also after treatment with medication. There are various psychological treatments aiming to improve these symptoms, but it is not known if they work or not.

The goal of this clinical trial is to evaluate group cognitive behavioural therapy (CBT) for adults with attention deficit hyperactivity disorder (ADHD) in comparison to an active control group consisting of a discussion and activity group. Previous research suggests that group CBT works about equally well as other structured group activities. The main questions the researchers aim to answer are if group CBT work better than activity groups to:

  • Improve symptoms of ADHD
  • Improve general mental health and life quality
  • Improve every-day functioning

The researchers also want to learn if group CBT or activity groups work better for some people with ADHD depending on individual characteristics such as

• type of symptoms, age, gender or co-occurring psychiatric diagnoses.

The comparison is a manualised structured activity group given at the same number of sessions and same group size. All participants will visit our clinics at 12 occasions. The partipants will:

  • Fill in questionnaires before and after the group intervention, and online after 6 and 12 months
  • Do cognitive testing before and after the intervention

Aperçu de l'étude

Description détaillée

Despite medical treatment, many adults with ADHD experience residual symptoms that negatively affect work performance and social life. Hence, several psychological interventions targeting these symptoms have been developed, but the treatment effects are still unclear due to lack of controlled clinical trials.

In this single-blind randomised controlled clinical trial, the reseachers will evaluate the effects of group CBT based on Safren's manual "CBT for ADHD/Mastering Your Adult ADHD" compared to an active control group. The control intervention is a manualised activity group that contains the same non-specific therapeutic elements as the treatment but no active CBT components. For dose equivalence, activity groups will be given with the same same number and length of sessions, and the same frequency, as the treatment conditions. Since therapist experience is known to influence outcomes, the activity groups will be held by staff with equivalent training and experience to those giving the treatment groups.

Consenting patients assessed eligible for treatment will be randomly assigned to treatment or control group using a standard digital randomisation generator with an allocation of 1:1. Patients and clinicians rating outcomes will be blind to group assignment.

Pre- and post intervention, and at 6 months and 12 months follow-up, the patient's ADHD symptoms, symptoms of anxiety and depression and general functioning will be assessed by experienced clinicians and with validated self-rating scales. Treatment fidelity and expectation will be compared for the therapy and control groups and adverse events will be registered.

An exact power calculation for estimation of sample sizes cannot be performed since effect sizes are not known. Based on a previously published studies of Safren's CBT individually administered, and general consensus of what is a clinically meaningful improvement in psychological treatments for other psychiatric diagnoses, we expect that 60 patients per arm will be sufficient for detection of clinically relevant effect sizes of approximately Cohen's d 0.3-0.4. A statistician will make a blind Bayesian stop analysis for every 20-25 patients, and based on the results we can decide to halt the study if sufficient power has been achieved earlier than after 60 patients. Full attrition analysis with intention to treat (ITT) analysis will be performed to investigate and minimize attrition bias.

Type d'étude

Interventionnel

Inscription (Réel)

226

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Sweden
      • Gothenburg, Sweden, Suède
        • Sahgrenska University Hospital

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Fulfilling criteria for ADHD
  • motivation and practical possibility to participate in the treatment.

Exclusion Criteria:

  • Ongoing psychosis or suicidality, severe self-injury,
  • Intellectual disability
  • Insufficient Swedish language skills.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Tripler

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Group cognitive behavioural therapy

Group CBT based on an adapted version of individual CBT for ADHD according to Safren's manual "CBT for ADHD/Mastering Your Adult ADHD".

CBT based on Safren's manual "CBT for ADHD/Mastering Your Adult ADHD"20 adapted for group format. The program includes psychoeducation and cognitive restructuring and aims to improve ADHD symptoms, especially planning, organisation, attention and adaptive thinking. The CBT groups will meet at the clinic weekly for 12 weeks for 2 hours including a break in the middle. The groups are led by two clinicians.

Comparateur actif: Activity group

The Activity group is a structured manualised group intervention designed by clinicians and researchers at Sahlgrenska University Hospital.

The Activity group is a structured manualised group intervention designed for this and planned future studies of psychosocial treatments for adults with ADHD and/or autism. The program includes group discussions, peer-sharing and social every-day life activities. The Activity groups will meet at the clinic weekly for 12 weeks for 2 hours including a break in the middle. The groups are led by two trainers.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change in Adult ADHD Self-Report Scale (ASRS)
Délai: From enrollment to the follow-up 12 months after end of treatment

ASRS is a self-reported symptom questionnaire for adults with ADHD. It has 18 questions about how often the participant experiences a certain symptom, with five response choices ranging from 0 (never) to 4 (very often) points.

From enrollment to the follow-up 12 months after end of treatment
Change in Clinical Global Impressions-Severity (CGI-S)
Délai: At enrollment and after 12 weeks at end of treatment

CGI-S is a 7-point scale where the clinician rate the severity of the patients illness at the time of assessment.

At enrollment and after 12 weeks at end of treatment

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Clinical Outcomes in Routine Evaluation - Outcome Measure (CORE-OM)
Délai: From enrollment to the follow-up 12 months after end of treatment

CORE-OM is a self-rating questionnaire covering general psychiatric symptoms, well-being and functioning. It has 34 questions about how often the participant experiences a certain symptom, with five response choices ranging from 0 (not at all) to 4 (most or all of the time) points.

From enrollment to the follow-up 12 months after end of treatment
Brunnsviken Brief Quality of Life Inventory (BBQ)
Délai: From enrollment to the follow-up 12 months after end of treatment

BBQ is a validated brief version of the self-rating Quality of Life Scale, with higher sensitivity to change. It consists of 12 statements and the participant indicates how much they agree with each statement in five response choices ranging from 0 (do not agree at all) to 4 (agree completely).

From enrollment to the follow-up 12 months after end of treatment
Colour word Interference Test (CWIT)
Délai: At enrollment and after 12 weeks at end of treatment

The cognitive task CWIT from the Delis-Kaplan Executive Function System (D-KEFS) is a version of the Stoop test aiming to measure switching and inhibition.

At enrollment and after 12 weeks at end of treatment
Trail Making Test (TMT)
Délai: At enrollment and after 12 weeks at end of treatment

The cognitive test TMT from the Delis-Kaplan Executive Function System (D-KEFS) is used to measure processing speed and cognitive flexibility.

At enrollment and after 12 weeks at end of treatment

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Treatment Credibility questionnaire (TCS)
Délai: At enrollment and after 12 weeks at end of treatment

Swedish version of the TCS for assessment of treatment fidelity and expectation in both participants with ADHD and clinicians administering the CBT and activity groups.

At enrollment and after 12 weeks at end of treatment

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

10 septembre 2024

Achèvement primaire (Réel)

30 juin 2026

Achèvement de l'étude (Réel)

30 juin 2026

Dates d'inscription aux études

Première soumission

17 septembre 2024

Première soumission répondant aux critères de contrôle qualité

17 septembre 2024

Première publication (Réel)

20 septembre 2024

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

21 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

16 septembre 2026

Dernière vérification

1 août 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • EPM Dnr 2024-02227-01
  • 2023 (Subvention/contrat des NIH des États-Unis)
  • 2023-01505 (Autre subvention/numéro de financement: Forte)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Description du régime IPD

Most individual data will be part of patients medical records.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner